| Literature DB >> 12799033 |
Anna Paola Batocchi1, Mario Rotondi, Marcella Caggiula, Giovanni Frisullo, Francesca Odoardi, Viviana Nociti, Carlo Carella, Pietro Attilio Tonali, Massimiliano Mirabella.
Abstract
The role of leptin was investigated in relapsing-remitting multiple sclerosis (MS). Control and MS patients showed comparable baseline serum leptin levels. During the first year of IFNbeta-1a treatment, leptin significantly decreased since 2 months after starting therapy in 11 patients who had no relapses. A significant decrease in IL12/IL10 ratio was observed in this group of patients only after 1 year of treatment. An increase of leptin was observed before the first clinical exacerbation in 13 relapsing patients. Leptin may play a pathogenic role in MS and can be a useful marker of disease activity and response to therapy.Entities:
Mesh：
Substances：
Year: 2003 PMID： 12799033 DOI： 10.1016/s0165-5728(03)00154-1
Source DB: PubMed Journal: J Neuroimmunol ISSN： 0165-5728 Impact factor: 3.478